Comprehensive clinical and molecular portraits of grade 3 ER+ HER-breast cancer

被引：1
|
作者：
Wang, K. [1 ]
Franch-Exposito, S. [2 ]
Li, L. [3 ]
Xiang, T. [4 ]
Wu, J. [3 ]
Ren, G. [4 ]
机构：
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine & Breast Surg, Chongqing, Peoples R China
[2] Inst Invest Biomed August Pi i Sunyer IDIBAPS, Gastrointestinal & Pancreat Oncol Team, Barcelona, Spain
[3] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai, Peoples R China
[4] Chongqing Med Univ, Affiliated Hosp 1, Key Lab Mol Oncol & Epigenet, Chongqing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.03.168
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
34P
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [11] Dysregulated expression of repetitive DNA in ER+/HER2-breast cancer
    Yandim, Cihangir
    Karakulah, Gokhan
    CANCER GENETICS, 2019, 239 : 36 - 45
  • [12] Tumor infiltrating lymphocytes (TILs) in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Esposito, A.
    Viale, G.
    Curigliano, G.
    CANCER RESEARCH, 2019, 79 (04)
  • [13] Therapeutic targeting of Rac GTPases in ER+ and HER2+breast cancer
    Hampsch, R. A.
    Shee, K.
    Miller, T. W.
    CANCER RESEARCH, 2016, 76
  • [14] APOBEC driving genomic evolution in ER+/HER2-breast cancer
    Bos, M.
    Smid, M.
    Sleijfer, S.
    Martens, J.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S105 - S106
  • [15] Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR−/HER2+ breast cancer subtypes
    Wu Ding
    Dengfeng Ye
    Haifeng Chen
    Yingli Lin
    Zhian Li
    Chuanjian Tu
    Breast Cancer, 2024, 31 : 295 - 304
  • [16] Molecular stratification of ER+/HER2-breast cancer cell lines to predict sensitivity to targeted agents
    Bathurst, L.
    Liao, L.
    Crozier, C.
    Lyttle, N.
    Marcellus, R.
    Bayani, J.
    Al-Awar, R.
    Bartlett, J.
    Spears, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [17] Role of her3 signaling pathways in er+ and her2+breast cancers
    Mishra, Rosalin
    Alanazi, Samar
    Patel, Hima
    Yuan, Long
    Garrett, Joan T.
    CANCER RESEARCH, 2019, 79 (13)
  • [18] Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics
    E. H. Lips
    L. Mulder
    J. J. de Ronde
    I. A. M. Mandjes
    A. Vincent
    M. T. F. D. Vrancken Peeters
    P. M. Nederlof
    J. Wesseling
    S. Rodenhuis
    Breast Cancer Research and Treatment, 2012, 131 : 827 - 836
  • [19] β2-microglobulin has a different regulatory molecular mechanism between ER+ and ER- breast cancer with HER2-
    Chai, Dandan
    Li, Kesheng
    Du, Huifen
    Yang, Suisheng
    Yang, Rong
    Xu, Yang
    Lian, Xiaowen
    BMC CANCER, 2019, 19 (1)
  • [20] ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER2+ Breast Cancer
    Arciero, Cletus A.
    Guo, Yi
    Jiang, Renjian
    Behera, Madhusmita
    O'Regan, Ruth
    Peng, Limin
    Li, Xiaoxian
    CLINICAL BREAST CANCER, 2019, 19 (04) : 236 - 245
12345